More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group

被引：0
|
作者：
Langerbeins, P. [1 ]
Busch, R. [2 ]
Schweighofer, C. D. [1 ]
Mueller, C. [1 ]
Fischer, K. [1 ]
Fink, A. -M. [1 ]
Cramer, P. [1 ]
Faetkenheuer, G. [1 ]
Hartmann, P. [1 ]
Stilgenbauer, S. [3 ]
Boettcher, S. [4 ]
Wendtner, C. -M. [5 ]
Hallek, M. [1 ]
Eichhorst, B. [1 ]
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[2] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[4] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany
[5] Klinikum Schwabing, Dept Internal Med 1, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V572
引用
收藏
页码：185 / 185
页数：1
相关论文
共 50 条
  • [41] Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
    Herishanu, Yair
    Tadmor, Tamar
    Braester, Andrei
    Bairey, Osnat
    Aviv, Ariel
    Rahimi-Levene, Naomi
    Fineman, Riva
    Levi, Itai
    Yuklea, Mona
    Ruchlemer, Rosa
    Shvidel, Lev
    Polliack, Aaron
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (02) : 185 - 192
  • [42] Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: A study by the German CLL Study Group
    Eichhorst, Barbara F.
    Busch, Raymonde
    Obwandner, Tanja
    Kuhn-Hallek, Ingrid
    Herschbach, Peter
    Hallek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1722 - 1731
  • [43] Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101
    Lin, Thomas S.
    Donohue, Kathleen A.
    Lucas, Margaret S.
    Byrd, John C.
    Bengtson, Elizabeth M.
    Peterson, Bercedis L.
    Larson, Richard A.
    BLOOD, 2007, 110 (11) : 232A - 233A
  • [44] Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of younger patients (PTS) with chronic lymphocytic leukemia (CLL): Results of a phase III study of the German CLL Study Group (GCLLSG)
    Eichhorst, B
    Busch, R
    Emmerich, B
    Hallek, M
    ANNALS OF ONCOLOGY, 2005, 16 : 89 - 90
  • [45] Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
    Smolej, Lukas
    Brychtova, Yvona
    Cmunt, Eduard
    Doubek, Michael
    Spacek, Martin
    Belada, David
    Simkovic, Martin
    Stejskal, Lukas
    Zygulova, Irena
    Urbanova, Renata
    Brejcha, Martin
    Zuchnicka, Jana
    Mocikova, Heidi
    Kozak, Tomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 769 - 778
  • [46] Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): Results of a meta-analysis of two phase III trials of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2005, 106 (11) : 213A - 213A
  • [47] A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years - End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
    Mulligan, Stephen P.
    Gill, Devinder S.
    Turner, Paul
    Renwick, William E. P.
    Harrup, Rosemary
    Latimer, Maya
    Mackinlay, Naomi
    Berkahn, Leanne
    Simpson, David
    Campbell, Philip
    Tiley, Campbell
    Cull, Gavin
    Collins, Marnie
    Cortissos, Paul
    Sulda, Melanie
    Best, Giles
    Kuss, Bryone J.
    BLOOD, 2012, 120 (21)
  • [48] A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRM Cancer Research Group (E1912)
    Shanafelt, Tait D.
    Wang, Victoria
    Kay, Neil E.
    Hanson, Curtis A.
    O'Brien, Susan M.
    Barrientos, Jacqueline C.
    Erba, Harry P.
    Stone, Richard M.
    Litzow, Mark R.
    Tallman, Martin S.
    BLOOD, 2018, 132
  • [49] SEQUENTIAL THERAPY OF FLUDARABINE, MITOXANTRONE AND CYCLOPHOSPHAMIDE (FMC) INDUCTION FOLLOWED BY ALEMTUZUMAB CONSOLIDATION IS EFFECTIVE AND SAFE IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) - RESULTS FROM A MULTICENTER PHASE II TRIAL OF THE GERMAN CLL STUDY GROUP
    Hopfinger, G.
    Busch, R.
    Eichhorst, B.
    Westermann, A.
    Fink, A.
    Cramer, P.
    Weit, N.
    Pflug, N.
    Reinart, N.
    Winkler, D.
    Fingerle-Rowson, G.
    Stilgenbauer, S.
    Kandler, G.
    Doehner, H.
    Hallek, M.
    Herling, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 124 - 124
  • [50] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (FIT Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CIA, and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang" (GOELAMS): CLL2007FMP (for fit medically patients)
    Lepretre, Stephane
    Aurran, Therese
    Mahe, Beatrice
    Cazin, Bruno
    Tournihlac, Olivier
    Maisonneuve, Herve
    Casasnovas, Olivier
    Delmer, Alain
    Leblond, Veronique
    Royer, Bruno
    Corront, Brigitte
    Chevret, Sylvie
    Delepine, Roselyne
    Vaudaux, Sandrine
    Van Den Neste, Eric
    Bene, Marie-Christine
    Cymbalista, Florence
    Feugier, Pierre
    BLOOD, 2009, 114 (22) : 225 - 225
12345